{"id":"aav-optirpe65","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AAV OPTIRPE65 is a gene therapy that uses adeno-associated virus (AAV) to deliver a functional copy of the RPE65 gene to the retina, treating inherited retinal dystrophies.","oneSentence":"Gene therapy targeting RPE65","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:21.579Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Leber congenital amaurosis"},{"name":"Retinitis pigmentosa"}]},"trialDetails":[{"nctId":"NCT02946879","phase":"","title":"Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)","status":"COMPLETED","sponsor":"MeiraGTx UK II Ltd","startDate":"2016-11","conditions":"Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AAV OPTIRPE65","genericName":"AAV OPTIRPE65","companyName":"MeiraGTx UK II Ltd","companyId":"meiragtx-uk-ii-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Gene therapy targeting RPE65 Used for Leber congenital amaurosis, Retinitis pigmentosa.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}